On May 14, 2026, the State Administration for Market Regulation (SAMR) released the 2026 Mandatory National Standard Development and Revision Plan (Second Batch), designating three standards — GB 9706.1-2025 (Safety of Medical Electrical Equipment), YY/T 1833-2025 (Clinical Validation of AI-based Medical Imaging Software), and YY 0567-2026 (Performance Requirements for Steam Sterilizers) — for immediate implementation. All manufacturers are required to complete compliance alignment by the end of Q3 2026. This move directly affects China’s medical device export competitiveness, particularly in markets requiring CE or FDA conformity assessments.

Event Overview

On May 14, 2026, SAMR announced the second batch of its 2026 mandatory national standard revision plan. The notice explicitly identifies GB 9706.1-2025, YY/T 1833-2025, and YY 0567-2026 as ‘immediate conversion’ items, mandating full enterprise compliance by Q3 2026. No transitional period is specified in the official document. The stated objective is to strengthen technical equivalence with international regulatory frameworks, especially for export-oriented medical device certification.

Industries Affected

Direct trading enterprises: Exporters of medical imaging systems and sterilization equipment face accelerated timelines for conformity documentation and third-party testing. Since CE and FDA pathways increasingly reference harmonized standards, late or partial adoption may delay market access in the EU and U.S., especially for Class II and III devices where clinical validation and electrical safety are subject to scrutiny.

Raw material procurement enterprises: Suppliers of critical components — such as high-purity stainless steel for sterilizer chambers, radiation-shielded enclosures for imaging devices, or validated AI training datasets — must now align their specifications and traceability protocols with the new standards. For example, YY/T 1833-2025 requires documented clinical validation workflows; suppliers providing annotated imaging data or algorithmic libraries will need to verify chain-of-custody and clinical use-case relevance.

Manufacturing enterprises: Device manufacturers must revise internal quality management systems (QMS), update risk management files per ISO 14971:2019, and conduct re-validation of software and hardware subsystems. Notably, GB 9706.1-2025 introduces updated requirements for programmable electrical medical systems (PEMS), affecting both legacy product lines and new designs. Production line recalibration and staff retraining are expected to begin before Q3 2026.

Supply chain service enterprises: Certification bodies, testing labs, and regulatory consultants must expand capacity for GB 9706.1-2025 testing (e.g., dielectric strength, leakage current under fault conditions) and YY/T 1833-2025 clinical validation audits. Demand for bilingual (CN/EN) technical documentation review and post-market surveillance support is projected to rise, particularly among SMEs lacking in-house regulatory affairs teams.

Key Focus Areas and Recommended Actions

Review existing product portfolios against the three standards’ scope and effective dates

Manufacturers should map each active model to applicable clauses — e.g., whether AI image analysis modules fall under YY/T 1833-2025’s definition of ‘clinical decision support software’. Prioritization should be based on export destination, risk classification, and current certification status.

Initiate gap analysis for QMS and technical documentation by June 2026

Internal audits must assess compliance with new requirements, including enhanced cybersecurity provisions in GB 9706.1-2025 and statistical validation protocols in YY/T 1833-2025. Documentation updates should include revised risk management files, updated verification reports, and traceability matrices linking requirements to test cases.

Engage accredited testing laboratories early to secure slots

Testing capacity for steam sterilizer performance (YY 0567-2026) and PEMS safety (GB 9706.1-2025) is already constrained. Early engagement helps avoid bottlenecks in Q3, when demand peaks ahead of the deadline.

Update labeling, user manuals, and IFUs to reflect new compliance statements

Per SAMR’s enforcement guidance, products placed on the market after Q3 2026 must carry updated conformity markings and declarations referencing the 2025/2026 versions. Multilingual IFUs must incorporate new warnings and operational limits defined in the revised standards.

Editorial Perspective / Industry Observation

Observably, this acceleration signals a strategic shift from ‘harmonization by alignment’ to ‘harmonization by mandate’. Unlike previous phased rollouts, SAMR has eliminated grace periods for these three standards — suggesting growing confidence in domestic testing infrastructure and regulatory readiness. Analysis shows that the timing coincides with pending revisions to EU MDR Annex I and FDA’s upcoming AI/ML-based SaMD guidance, implying coordinated timing to reduce future misalignment. From an industry perspective, the focus on AI clinical validation (YY/T 1833-2025) and sterilizer performance (YY 0567-2026) reflects prioritization of two high-risk, high-growth segments where Chinese firms hold increasing global market share — but also face intensified scrutiny.

Conclusion

This policy action does not merely tighten technical requirements; it recalibrates China’s position in global medical device regulation. Rather than reacting to external standards, SAMR is now proactively shaping interoperability expectations — especially for AI-enabled diagnostics and infection control equipment. A rational interpretation is that this represents institutional maturation: less about catching up, more about co-defining quality benchmarks across borders.

Source Attribution

Official source: State Administration for Market Regulation (SAMR), 2026 Mandatory National Standard Development and Revision Plan (Second Batch), issued May 14, 2026. Full text available at www.samr.gov.cn/bzgl/. Note: Implementation guidance documents, interpretation bulletins, and accredited lab lists remain pending publication and are under continuous monitoring.